<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04104646</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-06563AA1-02</org_study_id>
    <nct_id>NCT04104646</nct_id>
  </id_info>
  <brief_title>CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome</brief_title>
  <acronym>NOWSHINE</acronym>
  <official_title>A Phase II, Multicenter, Double Blind, Double Dummy, Randomized, 2 Arms Parallel Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study to&#xD;
      evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with Neonatal Opioid&#xD;
      Withdrawal Syndrome&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind, double-dummy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of treatment defined as the number of hours from first dose of study drug administration until the last dose of study drug</measure>
    <time_frame>up to 10 weeks after first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first weaning, defined as the number of hours from first dose of study drug administration until the first dose reduction</measure>
    <time_frame>up to 10 weeks after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for adjunctive drug therapy (phenobarbital) for signs of NOWS</measure>
    <time_frame>up to 10 weeks after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hours of treatment with adjunctive therapy</measure>
    <time_frame>up to 10 weeks after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for rescue doses (CHF6563 or morphine)</measure>
    <time_frame>up to 10 weeks after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of total dose which is from rescue doses</measure>
    <time_frame>up to 10 weeks after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of opioid related hospital stay, defined as number of days from day of birth until 48 hours after the final dose of drug treatment for NOWS</measure>
    <time_frame>up to 10 weeks plus 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse of NOWS, defined as experiencing recurrence of significant signs of withdrawal</measure>
    <time_frame>up to 6 weeks after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of readmissions, defined as readmission to hospital for NOWS relapse</measure>
    <time_frame>up to 6 weeks after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Neonatal Opioid Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>CHF6563</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual dose of CHF6563 and the corresponding oral dose of morphine matched placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral dose of morphine and the corresponding sublingual dose of CHF6563 matched placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF6563</intervention_name>
    <description>Sublingual CHF6563 administration at starting dose of 10 µg/Kg q8</description>
    <arm_group_label>CHF6563</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Oral morphine administration at starting dose of 0.07 mg/Kg q4</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF6563 matched placebo</intervention_name>
    <description>Sublingual CHF6563 matched placebo administration</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine matched placebo</intervention_name>
    <description>Oral morphine matched placebo administration</description>
    <arm_group_label>CHF6563</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained by parents/legal representative(according to local&#xD;
             regulation) prior to or after birth.&#xD;
&#xD;
          2. Birth weight ≥ 3rd centile for gestational age (GA), according to the CDC growth chart&#xD;
&#xD;
          3. Gestational age ≥ 36 weeks&#xD;
&#xD;
          4. Exposure to opioids during the last month of fetal life&#xD;
&#xD;
          5. Signs of neonatal opioid withdrawal syndrome requiring treatment, and the sum of 3&#xD;
             consecutive FNAST scores is ≥ 24 or a single score ≥ 12&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Familial history of prolonged QTc syndrome&#xD;
&#xD;
          2. Major congenital malformations or evidence of congenital infection&#xD;
&#xD;
          3. Signs of fetal alcohol spectrum disorders&#xD;
&#xD;
          4. Maternal alcohol abuse, defined as average of 3 or more drinks per week in the last 30&#xD;
             days&#xD;
&#xD;
          5. Medical illness at the time of randomization, including but not exclusively:&#xD;
&#xD;
               1. Neonatal hypoglycemia requiring intravenous glucose therapy&#xD;
&#xD;
               2. Neonatal respiratory illness requiring non-invasive or invasive respiratory&#xD;
                  support&#xD;
&#xD;
               3. Neonatal encephalopathy (including hypoxic ischemic encephalopathy or seizures&#xD;
&#xD;
               4. Severe hyperbilirubinemia-bilirubin at or above the exchange transfusion&#xD;
                  threshold as defined by the AAP&#xD;
&#xD;
               5. Severe elevation of serum aminotransferases (more than twice the upper limit of&#xD;
                  the age appropriate aminotransferases reference range of the investigational&#xD;
                  site).&#xD;
&#xD;
               6. Proven or suspected early onset neonatal infection which will require more than&#xD;
                  48hours treatment with antibiotics&#xD;
&#xD;
          6. Unable to tolerate an oral or sublingual medication&#xD;
&#xD;
          7. Need for medications forbidden in this study protocol&#xD;
&#xD;
          8. Any condition that, in the opinion of the Investigator, would place the neonate at&#xD;
             undue risk&#xD;
&#xD;
          9. Participation in another clinical trial of any medicinal product, placebo,&#xD;
             experimental medical device or biological substance conducted under the provisions of&#xD;
             a protocol on the same therapeutic target. The participation in studies involving&#xD;
             diagnostic devices or treatments for conditions other than NOWS and NAS may be&#xD;
             permitted following an agreement with the Sponsor. Non-interventional observational&#xD;
             studies are allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Kraft</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Info</last_name>
    <phone>+39.0521 2791</phone>
    <email>clinicaltrials_info@chiesi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical site 015</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

